Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-19
    E.g., 2018-02-19

Articles

8633 items
8:50 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Patient sample, rat and mouse studies suggest inhibiting HDAC2 could help treat diastolic dysfunction. In postmortem myofibrils from heart failure patients, diastolic relaxation time was longer than in matched samples from unaffected donors,...
8:49 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Inflammation; infectious disease

INDICATION: Inflammatory disease; sepsis In vitro and mouse studies suggest inhibiting the MAC-1-CD40L interaction could help treat systemic inflammatory response syndrome (SIRS) and sepsis. In a mouse cell-based assay, a mAb against the M7 motif ligand-binding...
8:49 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest CXCL12-secreting Lactobacillus reuteri could help treat wounds. In a human skin biopsy-based model of wound healing, L. reuteri engineered to secrete CXCL12 increased the length of epidermal sleeves...
8:49 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Musculoskeletal

INDICATION: Musculoskeletal Frog studies suggest DDX21 mRNA could help treat Treacher Collins syndrome, a craniofacial disorder caused by mutations in the TCOF1 or Pol I genes. In a Xenopus embryo model of the syndrome, injection of...
8:27 AM, Feb 07, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest inhibiting RAF1 could help treat KRAS-driven lung cancer. In tumor cells from two patient-derived xenograft (PDX) mouse models of KRAS-driven lung cancer, shRNA targeting RAF1 encoded in...
8:27 AM, Feb 07, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting IL-1α or IL-6 could help treat HER2-positive breast cancer. In patient tumor samples, levels of IL-1α or IL-6 were associated with poor metastasis-free survival, and high...
8:25 AM, Feb 07, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Lymphoma; breast cancer; colorectal cancer Mouse studies suggest intratumoral injection of a TLR9 agonist and an agonist antibody against OX40 could help treat lymphoma, breast cancer and colorectal cancer. In a mouse model of...
8:25 AM, Feb 07, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest a soluble form of SLAMF6 could enhance the effectiveness of T cell therapies for melanoma. In cultures of activated and expanded human tumor-infiltrating lymphocytes and mouse lymphocytes, a...
9:09 AM, Feb 06, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting HHAT could help treat colorectal cancer. In colorectal cancer cells from patients, siRNA targeting HHAT decreased spheroid formation and size compared with non-specific...
9:09 AM, Feb 06, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Mouse studies suggest inhibiting PERK or IRE1 could help prevent embryonic microcephaly caused by Zika infection. In a mouse embryo model of Zika infection, tool compound PERK or IRE1 inhibitors decreased microcephaly compared...

Pages